Identification of HSP90 inhibitors as a novel class of senolytics

Heike Fuhrmann-Stroissnigg, Yuan Yuan Ling, Jing Zhao, Sara J. McGowan, Yi Zhu, Robert W. Brooks, Diego Grassi, Siobhan Q. Gregg, Jennifer L. Stripay, Akaitz Dorronsoro, Lana Corbo, Priscilla Tang, Christina Bukata, Nadja Ring, Mauro Giacca, Xuesen Li, Tamara Tchkonia, James L. Kirkland, Laura J. Niedernhofer, Paul D. Robbins

Research output: Contribution to journalArticlepeer-review

414 Scopus citations


Aging is the main risk factor for many chronic degenerative diseases and cancer. Increased senescent cell burden in various tissues is a major contributor to aging and age-related diseases. Recently, a new class of drugs termed senolytics were demonstrated to extending healthspan, reducing frailty and improving stem cell function in multiple murine models of aging. To identify novel and more optimal senotherapeutic drugs and combinations, we established a senescence associated β-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells. We used primary Ercc1 -/- murine embryonic fibroblasts with reduced DNA repair capacity, which senesce rapidly if grown at atmospheric oxygen. This platform was used to screen a small library of compounds that regulate autophagy, identifying two inhibitors of the HSP90 chaperone family as having significant senolytic activity in mouse and human cells. Treatment of Ercc1 mice, a mouse model of a human progeroid syndrome, with the HSP90 inhibitor 17-DMAG extended healthspan, delayed the onset of several age-related symptoms and reduced p16INK4a expression. These results demonstrate the utility of our screening platform to identify senotherapeutic agents as well as identified HSP90 inhibitors as a promising new class of senolytic drugs.

Original languageEnglish (US)
Article number422
JournalNature communications
Issue number1
StatePublished - Dec 1 2017

Bibliographical note

Funding Information:
We are grateful for the experimental support by Amira Barghouthy and Colten Lankford. This work was supported by the NIH grants AG043376 (Project 2 and Core A: PDR, Project 1 and Core B: LJN), AG13925 (JLK), DK50456 (JLK: Adipocyte Subcore), the Connor Group and the Noaber, Ted Nash, and Glenn Foundations (JLK), the American Federation for Aging Research (JLK), and Aldabra Biosciences (PDR and LJN).

Publisher Copyright:
© 2017 The Author(s).


Dive into the research topics of 'Identification of HSP90 inhibitors as a novel class of senolytics'. Together they form a unique fingerprint.

Cite this